HCPLive Network

Drug Reduces Progression to Clinically Definite MS

Friday, April 20 (HealthDay News) --  As part of a Phase 3 trial, Mark Freedman, M.D., from the University of Ottawa in Canada, and colleagues randomly assigned 517 individuals who had a first clinical demyelinating event and brain lesions detected by magnetic resonance imaging (MRI) to a subcutaneous serum-free formulation of IFN β-1a one or three times a week, or placebo. Placebo patients were switched to IFN β-1a three times a week after two years or after a diagnosis of clinically definite MS.

At three years, the researchers found that the probability of developing clinically definite MS was 41.3 percent for placebo patients switched to IFN β-1a, but was significantly lower for those who received IFN β-1a once a week (27.6 percent) or three times a week (27.1 percent). Similar results were found for the probability of a McDonald MS diagnosis, at 86.5, 79.1, and 66.8 percent, respectively.

"While doses three times a week and once a week equally delayed a clinically definite MS diagnosis without MRI measures, there were significantly more benefits in taking the drug three times a week compared with once a week when it came to brain lesion changes and other McDonald criteria for diagnosing MS," Freedman said in a statement.

The study was supported by Merck Serono S.A.

Press Release
More Information

Individuals suspected of having multiple sclerosis are less likely to be diagnosed with clinically definite disease if they soon start treatment with interferon β-1a, according to a study presented at the annual meeting of the American Academy of Neurology, held from April 21 to 28 in New Orleans.




Copyright © 2012 HealthDay. All rights reserved.


Further Reading
Assessment of long-term data on treatment utility demonstrates the effectiveness and cost-effectiveness of interferon-beta and glatiramer acetate for multiple sclerosis.
Treatment with Sativex oromucosal spray produces significant reductions in spasticity in patients with multiple sclerosis (MS) compared with placebo, but researchers reported no significant difference between the two in neurophysiologic measures.
Results from the RADIANCE study show that treatment with the selective S1P1 receptor modulator RPC1063 is associated with significant reductions in GD-enhancing lesions on MRI, as well as new or enlarging T2 lesions, compared with placebo.
Patients treated for two years with a combination of glatiramer acetate and estriol experienced a one-third reduction in relapse rate compared with patients who received glatiramer acetate and placebo.
Patients with multiple sclerosis who received thrice-weekly injections of glatiramer acetate 40 mg/ml reported increased satisfaction with their treatment and experienced lower rates of moderate and severe injections site reactions and other adverse events.
Five-year data from the ENDORSE study shows that patients with multiple sclerosis who continued treatment, or who switched from another medication, experienced improved NEDA outcomes.
Mikkel Anthonisan, MD, highlights his experience as the founder of Oceans of Hope, a global voyage to change the perception of multiple sclerosis, at the 2014 Joint ACTRIMS-ECTRIMS Meeting.
More Reading